Concepedia

Final Overall Survival (Os) Analysis from the Cleopatra Study of First-Line (1L) Pertuzumab (Ptz), Trastuzumab (T), and Docetaxel (D) in Patients (Pts) with Her2-Positive Metastatic Breast Cancer (Mbc)

Sandra M. Swain, S. Kim, Javier Cortés, J. Ro, Semiglazov Vf, Mario Campone, Eva Ciruelos, Jean-Marc Ferrero, Sarah Heeson, Emma Clark,

Annals of Oncology · 2014 · 37 citations · 0 references

Open access

Concepts

MedicineOncologyPharmacologyBreast OncologyCancer PharmacologyMetastasisBreast Cancer OncologyBreast Cancer PharmacotherapyCancer ImmunotherapyHer2-positive Breast CancerImmunotherapy For Breast CancerMetastatic Breast CancerBreast Cancer PrognosisHer2-positive Breast Cancer ImmunotherapyHer2-positive Breast Cancer TherapyHer2-positive Metastatic DiseaseMetastatic Breast Cancer TreatmentMetastatic Her2-positive Breast CancerPertuzumab Therapy